is semaglutide approved for weight loss in canada tablets Wegovy another GLP-1 medication by FDA and Health Canada Health Canada approves 1st generic

Other times, you'll find the criteria for coverage laid out

Therefore, a personalized approach to treatment is critical

When prescribing semaglutide, particularly in elderly patients, with pre-existing kidney disease or metabolic syndrome, and individuals receiving concomitant medications, careful monitoring is essential

Peaks async model trades clinical screening for speed, which works well for buyers who already understand GLP-1 treatment and want medication fast, less so for anyone who wants a clinician to review baseline labs first

Currently, Eli Lilly's GLP-1 weight-loss and diabetes drugs, Mounjaro (tirzepatide) and Zepbound (tirzepatide) are the global leaders, with combined 2025 revenue exceeding $36.5 billion and accounting for over 56% of the company's total revenue